New York Post

My latest favorite anti-aging device is 20% off on Amazon

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Contrary to popular belief, beauty doesn’t have to ...
The New York Times

The Best Red-Light Device

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rory Evans Rory Evans is a writer focused on skin-care and beauty products.
Morningstar

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma ...

MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new standard of care as early as first relapse RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & ...
Finanznachrichten

Johnson & Johnson: DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care? Approval marks the twelfth ...